Atossa Therapeutics
ATOS
19 hedge funds and large institutions have $688K invested in Atossa Therapeutics in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
293% more capital invested
Capital invested by funds: $175K → $688K (+$513K)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
58% more funds holding
Funds holding: 12 → 19 (+7)
0.01% more ownership
Funds ownership: 0.01% → 0.03% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$156K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$93.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$86.8K |
| 4 |
Barclays
London,
United Kingdom
|
+$83.4K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$52K |
| 2 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
-$10.9K |
| 3 |
Renaissance Technologies
New York
|
-$3K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$1K |
ATOS Hedge Fund Activity: Q1 2018 in Review
19 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2018, worth a combined $688K — up 293% from $175K a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATOS positions and 4 closed out — a net gain of 7 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $156K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $52K sold.
- 19 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2018, up from 12 in Q4 2017.
- Funds reported $688K of Atossa Therapeutics stock for Q1 2018, up 293% quarter-over-quarter.
- 11 funds opened new Atossa Therapeutics positions in Q1 2018 and 4 closed out, a net change of +7 holders.
- The largest Atossa Therapeutics buyer in Q1 2018 was Susquehanna International Group, an estimated $156K added.
- The largest Atossa Therapeutics seller in Q1 2018 was Panagora Asset Management, an estimated $52K sold.
Based on aggregated 13F filings for Q1 2018.